TIGIT (T cell immunoglobulin and ITIM domain), also named as WUCAM, Vstm3, and VSIG9, has been reported to possess the ability of suppressing both T cell-driven inflammation and T cell and NK cell-dependent anti-tumor immunity, as a coinhibitory receptor and a novel immune checkpoint [95,96]. Here, TIGIT is linked to neoplasm.